IQVIA's latest annual oncology report puts global spending on cancer medicines at $252 billion in 2024, up 75% over five years, with growth expected to slow from 2027 as key drugs lose exclusivity.
Spending on cancer medicines, not including additional medical costs or supportive care medicines, grew 75% over the last five years, reaching $252Bn in 2024.
Report summary, Key Findings
IQVIA's latest annual oncology report puts global spending on cancer medicines at $252 billion in 2024, up 75% over five years, with growth expected to slow from 2027 as key drugs lose exclusivity. Funder: IQVIA (commercial data and analytics vendor) self-funds the Institute's reports; no external funder or COI statement in the public summary. Counts cancer medicines only, worldwide – not US treatment costs, hospital services or supportive care. IQVIA sells the underlying data, so figures are its own estimates. No comparator. Study type: other.
